To develop new drugs or new formulations of existing drugs for patients suffering from the most neglected communicable diseases. Acting in the public interest, DNDi will bridge existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners.

DNDi’s primary focus will be the development of drugs for the most neglected diseases, such as sleeping sickness, leishmaniasis, and Chagas disease; and it will also consider engaging R&D projects on other neglected diseases. DNDi will address unmet needs by taking on projects that others are unable or unwilling to pursue and, as means permit, will consider development of diagnostics and/or vaccines.

In pursuing these goals, DNDi will manage R&D networks built on South-South and North-South collaborations. While using the existing support capacities in countries where the diseases are endemic, DNDi will help to build additional capacity in a sustainable manner through technology transfer in the field of drug research and development for neglected diseases.

VISION

To improve the quality of life and the health of people suffering from neglected diseases by using an alternative model to develop drugs for these diseases and by ensuring equitable access to new and field-relevant health tools. In this not-for-profit model, driven by the public sector, a variety of players collaborate to raise awareness of the need to research and develop drugs for those neglected diseases that fall outside the scope of market-driven R&D. They also build public responsibility and leadership in addressing the needs of these patients.

MISSION

To develop new drugs or new formulations of existing drugs for patients suffering from the most neglected communicable diseases. Acting in the public interest, DNDi will bridge existing R&D gaps in essential drugs for these diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners.

DNDi’s primary focus will be the development of drugs for the most neglected diseases, such as sleeping sickness, leishmaniasis, and Chagas disease; and it will also consider engaging R&D projects on other neglected diseases. DNDi will address unmet needs by taking on projects that others are unable or unwilling to pursue and, as means permit, will consider development of diagnostics and/or vaccines.

In pursuing these goals, DNDi will manage R&D networks built on South-South and North-South collaborations. While using the existing support capacities in countries where the diseases are endemic, DNDi will help to build additional capacity in a sustainable manner through technology transfer in the field of drug research and development for neglected diseases.
The Drugs for Neglected Diseases initiative (DNDi) is a patient-needs driven, not-for-profit research and development (R&D) organization that develops safe, effective, and affordable medicines for neglected diseases that afflict millions of the world’s poorest people.

DNDi focuses on developing new treatments for the most neglected patients suffering from diseases such as sleeping sickness (or human African trypanosomiasis), leishmaniasis, Chagas disease, malaria, specific filarial diseases, and paediatric HIV.

The initiative’s primary objective is to deliver 11 to 13 new treatments by 2018 and to establish a strong R&D portfolio for these diseases.
…and provided us the opportunity to reflect not only on our own work, achievements, and lessons learned, but also on the broader landscape of research and development (R&D) for neglected diseases and how it has evolved since DNDi was launched. It was also an opportunity to reinforce the voices and perspectives from the disease-endemic regions where DNDi is rooted, and to open our debates to questioning the future orientations of the organization.

The momentum today is a sign of advancement and engagement

One of the most striking outcomes of the 10-year reflection is that, while DNDi was established in what was a neglected disease R&D vacuum, we are now in a true landscape, with many initiatives and actors engaging in one way or another, albeit not yet in a coordinated manner. While admittedly this landscape is fragmented and even fragile in many ways, there is no doubt that the momentum today is a sign of advancement and engagement. But global progress has taken time to bear fruit. A recent analysis of the R&D pipeline for neglected diseases showed that the past ten years have only seen a small increase in the percentage of drugs and vaccines approved for neglected diseases, but that this slight increase was primarily in repurposing or combining existing drugs – so-called incremental improvements.

Truly new drugs have not yet made their way to the end of the development pipeline. While short-term improvements have had a great impact, that of a new, simple oral treatment for a deadly disease such as sleeping sickness for example, would be enormous, and requires greater resources and commitment, especially when such tools are vital to supporting the control and elimination targets established by the WHO.

DNDi started out as an experiment, and such experiments require innovation, risk taking, knowhow, anticipation, and solid partnerships. While the first decade of DNDi has rendered important results – six treatments delivered and a robust
drug development pipeline established, with 12 new chemical entities (NCEs) in pre-clinical and clinical development – it has also provided some key lessons that we will endeavor to translate into the DNDi of the next decade. To do this, we began by analysing the DNDi model and what we consider the four key pillars of the organization:

- the patient needs’ driven approach must remain central to our priority setting and decision making processes;
- a commitment to sharing knowledge and an access-oriented intellectual property policy are vital in a field where R&D incentive is lacking;
- diversifying and balancing funding sources ensures scientific independence; and
- innovative partnerships are crucial.

**Sustainability is the fundamental issue**

DNDi conducted this analysis in order to inform all stakeholders, partners, and donors who share DNDi’s vision and mission of the necessity of establishing a more sustainable framework for neglected disease R&D.

Sustainability is the fundamental issue. For example, sustaining and increasing funding is more important than ever as new chemical entities are reaching clinical trial phases, typically the most costly part of drug development. New incentives, new funding sources and mechanisms, including those that pool funding sources together to specifically target priority R&D, are essential. The financial fragility of many organizations is a constant threat to many crucial projects and is a disincentive to enter into – and stay in – the field. Another example concerns regulatory capacities in developing countries. In addressing developing countries’ health needs, many argue that stringent regulatory authorities are the only qualified institutions to evaluate medicines. However, only endemic countries themselves can assess the risks and benefits of health products for the diseases affecting their own populations. It is thus of paramount importance that the regulatory capacities of these countries be strengthened, and regional harmonization – where appropriate – be supported in the long term.

The DNDi model, while just one example, has experimented with new ways of partnering and conducting R&D for neglected diseases. By expanding on its own lessons learned after ten years, and as part of a global process of WHO member states to move towards a global framework for the financing and coordination of R&D for the priority health needs of developing countries, DNDi proposed projects aimed at demonstrating the principles laid forth by the WHO Consultative Expert Working Group (CEWG). ‘The Visceral Leishmaniasis Global R&D and Access Initiative’ was selected. It aims to demonstrate that coordination, transparency, capacity building, and innovative research and financing incentives can truly and effectively boost development and delivery of treatments for patients in need, and will ensure that the cost of treatments is not linked to the investment made in their development.

**Learn from all innovative approaches to ensure translation into an effective framework**

This process holds the promise of ensuring that needs, and not markets, will drive the development and delivery of essential health tools to those in need of them. But we will have to humbly learn and apply the lessons from DNDi and other experimental approaches to ensure translation into an effective framework, based on open models of innovation and access. With 70% of the world’s poor living in middle-income countries, the challenges of access to essential medicines need to be revisited and addressed in new ways.

DNDi will continue to work to deliver on its mandate, and to ensure that the future direction of the organization is one that is rooted in the needs of neglected patients and the innovation they deserve, both in terms of science and in how we operate, as we gear up for the next exciting decade.

---

“DNDi started out as an experiment, and requires innovation, risk taking, knowhow, anticipation, and solid partnerships”

---

Dr Bernard Pécoul

Prof. Marcel Tanner
DNDi’s is an alternative model to develop treatments for neglected diseases and ensure equitable access for all patients.
THE QUEST FOR A SIMPLE PILL IN A PATIENT’S HAND

DNDi clinical trial expertise has been developed across several diseases and over several continents. Today, clinical activities include more early phase trials to test entirely new drugs.

Since 2003, DNDi has developed clinical trial expertise across several disease areas and several continents. The regional disease-specific clinical research platforms it has supported and many other partners worldwide have together conducted 25 clinical studies in five disease areas so far, including malaria, visceral leishmaniasis (or kala-azar), cutaneous leishmaniasis, sleeping sickness, Chagas disease, and paediatric HIV. At any given time, some 10 clinical trials are simultaneously ongoing. Testing treatments at all stages of the drug development pipeline, from screening molecules to large-scale implementation studies in developing countries, has been a true experiment in innovative partnership.

Over a decade, and as investment made in both short- and long-term drug development approaches begins to bear fruit, DNDi’s clinical trials have somewhat shifted from being essentially later phase trials using existing drugs, to include more early phase trials testing entirely new drugs as well.

Regional rooting has been key
DNDi’s founding partners in endemic countries set the tone for a regionally embedded model for neglected disease R&D, and thus the setting-up of regional offices and regional disease-specific clinical research platforms (see page 45) were quick to follow the foundation of DNDi. Today, there are fully developed clinical research projects running in Asia, Africa, and Latin America. The latter has also begun to develop early-stage research capacities in the field (see LOLA, page 16) of neglected diseases, a first for DNDi. But before reaching the clinical research phase, proactive acquisition and investigation of compounds up to testing in healthy volunteers is conducted with a network of pharmaceutical, biotechnology, academic, and other research organizations worldwide, to ensure that the best compounds can reach clinical development.

A decade of conducting trials in patients in endemic areas – in what is, in some cases, considered the most challenging of clinical research environments – has reinforced several strategic decisions taken by the organization, notably in terms of the mix of public and private partners, endemic country embedment, capacity building as part and parcel of clinical research, short- and long-term approaches to drug development, and the strong commitment to patient access to treatments delivered.
Only regional investigators and medical field-oriented organizations have the expertise to contribute to clinical development in the field conditions in which DNDi’s target diseases are most prevalent. For example, in 2013, a Phase II, double-blind, randomized, controlled trial evaluating the safety and efficacy of the oral drug candidate E1224 against Chagas disease was completed, and provided key data that will drive the future research agenda for new treatment regimens. It was the first ever such trial conducted in Bolivia, and proved that it is possible to strengthen research capacity and conduct an international standard clinical trial in a resource-limited, developing-country setting. The capacity built with this trial is now in place, and – as with such DNDi-sponsored trials around the world – will be brought to bear on future clinical research in these countries. 

Clinical trials have direct impact

Clinical research also goes hand in hand with control and elimination strategies in many cases – the studies currently being undertaken for sleeping sickness in the Democratic Republic of the Congo, for example, are contributing to the treatment of patients both inside and outside of the trial, and have built capacity in the detection and treatment of the disease overall. In this way, the reach and impact of clinical research can go beyond just the delivery of a health tool. To date, over 33,000 patients have been enrolled in clinical and pharmacovigilance studies in or directly linked to DNDi projects. 

Because the clinical sites are often in remote areas, DNDi is committed to supporting improvements in clinical research infrastructure – including solar panels, laboratory equipment, waste management systems, internet connectivity, and other renovations so that patients can access clinical trial facilities as close as possible to where they live. These clinical research capacities in remote settings have resulted in increased numbers of patients who access treatments: a total of 7,700 patients who could not be included in the trials due to strict inclusion criteria, received the best possible treatment for their disease as an indirect result of the trial. Extensive training on the conduct and ethics of clinical trials is given to medical staff through the clinical research platforms. All DNDi-sponsored trials comply with international ethical and quality standards and are conducted in neglected disease-endemic regions (except for Phase I studies) in collaboration with local partners, as well as with support from international groups such as MSF. 

Increasing patient access to essential medicines

Clinical research also has a very important role to play in helping countries to adapt policies and thus to increasing patient access to essential medicines. Large-scale implementation studies, such as that conducted for ASAQ fixed-dose treatment against malaria and the current study for kala-azar treatments in India, are key to supporting national policy changes necessary to ensuring that the right treat-
ments are reaching the patients in need. It should be said, however, that clinical research alone does not constitute a sustainable model of R&D for neglected diseases.

Sustainable financing, enabling international policy frameworks, strengthening of regulatory capacities and priority setting by disease-endemic countries, health system strengthening, technology transfer for sustainable drug production, demand forecasting and procurement processes, to name but a few, are all part of a larger scope of issues that are required to ensure that a treatment is accessible, even when clinical development has delivered a safe, efficacious, and available treatment. DNDi has learned over the past decade that no one actor alone can ensure patient access to the best possible treatment.
DNDi BOARD MEMBERS

Marcel Tanner  
Chair; Swiss Tropical and Public Health Institute (Swiss TPH), Switzerland

Alice Dautry  
Institut Pasteur, France

Joanne Liu  
Médecins Sans Frontières (MSF) (as of Dec. 2013)

John Reeder  
[Permanent Observer] Special Programme for Research and Training in Tropical Diseases (WHO-TDR), Switzerland

Els Torreele  
Secretary, Open Society Foundations, USA

Abul Faiz  
Patient representative; Sir Salimullah Medical College, Bangladesh

Datuk Mohd Ismail  
Ministry of Health, Malaysia

Derrick Wong  
Treasurer; non-profit management consultant, France

Noor Hisham Abdullah  
Ministry of Health, Malaysia (as of Dec. 2013)

Carlos Morel  
Oswaldo Cruz Foundation (Fiocruz), Brazil

Jorge Bermudez  
Oswaldo Cruz Foundation (Fiocruz), Brazil (as of Dec. 2013)

Unni Karunakara  
Médecins Sans Frontières (MSF)

Bennett Shapiro  
Pure Tech Ventures, formerly with Merck & Co, USA

Christian Bréchot  
Institut Pasteur, France (as of Dec. 2013)

Paulina Tindana  
Patient representative; Navrongo Health Research Centre, Ghana

DNDi SCIENTIFIC ADVISORY COMMITTEE MEMBERS

Pierre-Etienne Bost, Chair; formerly with Institut Pasteur, France

Alice Dautry, Institut Pasteur, France

Joanne Liu, Médecins Sans Frontières (MSF) (as of Dec. 2013)

John Reeder, [Permanent Observer] Special Programme for Research and Training in Tropical Diseases (WHO-TDR), Switzerland

Khiran Bhatt, University of Nairobi, Kenya

Abdallah Daar, Professor, Public Health Sciences and Surgery, University of Toronto, Canada, and Chair, Advisory Board, UN University International Institute for Global Health, Switzerland

Joelle Tanguy, management consultant, France

J. Carl Craft, formerly with Medicines for Malaria Venture (MMV), Switzerland

Dale Kempf, AbdVie, USA

Els Torreele, founding chair, TDR/WHO, Switzerland

Simon Croft, London School of Hygiene and Tropical Medicine, UK

Lisa Frigati, Tygerberg Hospital, South Africa

Oswaldo Cruz Foundation (Fiocruz), Brazil

Yves Champney, former Chair, DNDi Board of Directors and founder, ITEEC, France

Federico Gomez de las Heras, formerly with GlaxoSmithKline, Spain (until April 2013)

Chitar Mal Gupta, Central Drug Research Institute, India

Simón Díez, Instituto de Salud Global, Spain

Abdallah Daar, Professor, Public Health Sciences and Surgery, University of Toronto, Canada, and Chair, Advisory Board, UN University International Institute for Global Health, Switzerland

Rowan Gillies, former President, MSF; International Council, Australia

Paul Kerr, research policy advisor, UK

Lalit Kant, Deputy Director, Immunization, Bill & Melinda Gates Foundation, and former representative, Board, Indian Council of Medical Research (ICMR), India

Philippe Desieux, specialist in Leishmaniasis, and former Senior Program Officer for Disease Control, IJWH, and former Leishmaniasis Research Coordinator, TDR/WHO, France

Stephen Lewis, Chair, Board of the Stephen Lewis Foundation, and former Minister of Foreign Affairs of Canada, formerly United Nations Special Envoy for HIV/AIDS in Africa, Canada

Ahmed El Hassan, Emeritus Professor, Institute of Endemic Diseases, University of Khartoum, Sudan

Sheba K. Meymandi, Director, Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center, USA

Rowan Gillies, former President, MSF; International Council, Australia

Lalit Kant, Deputy Director, Immunization, Bill & Melinda Gates Foundation, and former representative, Board, Indian Council of Medical Research (ICMR), India

Piero Olliaro, Head, Intervention and implementation research, WHO/TDR, Switzerland

Samih T. Darwazah, Professor, Public Health and Harvard Kennedy School, USA

Ricardo Preve, Film Director, Ricardo Preve Films LLC, Argentina

DNDi FRIENDS

Paulo Buss, specialist in Paediatrics and Public Health, and former President, Oswaldo Cruz Foundation (Fiocruz), Brazil

Joanne Liu, Médecins Sans Frontières (MSF) (as of Dec. 2013)

John Reeder, [Permanent Observer] Special Programme for Research and Training in Tropical Diseases (WHO-TDR), Switzerland

Khiran Bhatt, University of Nairobi, Kenya

Yves Champney, former Chair, DNDi Board of Directors and founder, ITEEC, France

Abdallah Daar, Professor, Public Health Sciences and Surgery, University of Toronto, Canada, and Chair, Advisory Board, UN University International Institute for Global Health, Switzerland

Joelle Tanguy, management consultant, France

J. Carl Craft, formerly with Medicines for Malaria Venture (MMV), Switzerland

Dale Kempf, AbdVie, USA

Els Torreele, founding chair, TDR/WHO, Switzerland

Simon Croft, London School of Hygiene and Tropical Medicine, UK

Lisa Frigati, Tygerberg Hospital, South Africa

Yves Champney, former Chair, DNDi Board of Directors and founder, ITEEC, France

Federico Gomez de las Heras, formerly with GlaxoSmithKline, Spain (until April 2013)

Chitar Mal Gupta, Central Drug Research Institute, India

Simón Díez, Instituto de Salud Global, Spain

Abdallah Daar, Professor, Public Health Sciences and Surgery, University of Toronto, Canada, and Chair, Advisory Board, UN University International Institute for Global Health, Switzerland

Rowan Gillies, former President, MSF; International Council, Australia

Lalit Kant, Deputy Director, Immunization, Bill & Melinda Gates Foundation, and former representative, Board, Indian Council of Medical Research (ICMR), India

Philippe Desieux, specialist in Leishmaniasis, and former Senior Program Officer for Disease Control, IJWH, and former Leishmaniasis Research Coordinator, TDR/WHO, France

Stephen Lewis, Chair, Board of the Stephen Lewis Foundation, and former Minister of Foreign Affairs of Canada, formerly United Nations Special Envoy for HIV/AIDS in Africa, Canada

Ahmed El Hassan, Emeritus Professor, Institute of Endemic Diseases, University of Khartoum, Sudan

Sheba K. Meymandi, Director, Center of Excellence for Chagas Disease at Olive View-UCLA Medical Center, USA

Piero Olliaro, Head, Intervention and implementation research, WHO/TDR, Switzerland

Samih T. Darwazah, Professor, Public Health and Harvard Kennedy School, USA

Ricardo Preve, Film Director, Ricardo Preve Films LLC, Argentina

DNDi REGIONAL OFFICE BOARD

Suerie Moon, Harvard School of Public Health and Harvard Kennedy School of Government, USA

James Orbinski, Centre for International Governance Innovation, Wilfrid Laurier University, Canada

Bernard Pécoul, Drugs for Neglected Diseases initiative (DNDi), Switzerland

DNDi/Latin America Board of Directors, Executive Members

Michel Lotrowska, Chair; Brazil

Vacant, Vice-president

Tyler Fainstat, Secretary; Médecins Sans Frontières (MSF), Brazil (until Sept. 2013)

Sue Rice, Director, Strategic Planning, DNDi, Switzerland

Tatiana Zanotti, Secretary; Médecins Sans Frontières (MSF), Brazil (as of Oct. 2013)

• Fiscal Council

• Advisory board

Carlos Morel, Center for Technological Development in Health (CUTS/Fiocruz), Brazil (until Sept. 2013)

Sergio Alejandro Sosa-Estani, Ministry of Health, Argentina (as of Oct. 2013)

Jorge Bermudez, Oswaldo Cruz Foundation (Fiocruz), Brazil (as of Oct. 2013)

DNDi North America Board of Directors

Bennett Shapiro, Chair; Pure Tech Ventures, formerly with Merck & Co, USA

Darin Portnoy, Secretary; Montefiore Medical Center and Family Health Center, USA

Joelle Tanguy, Treasurer; International Federation of Red Cross and Red Crescent Societies, Switzerland

Shing Chang, former R&D Director, DNDi, and consultant, global health-related drug discovery and development, USA

Suerie Moon, Harvard School of Public Health and Harvard Kennedy School of Government, USA

James Orbinski, Centre for International Governance Innovation, Wilfrid Laurier University, Canada

Bernard Pécoul, Drugs for Neglected Diseases initiative (DNDi), Switzerland

DNDi/Latin America Board of Directors, Executive Members

Michel Lotrowska, Chair; Brazil

Vacant, Vice-president

Tyler Fainstat, Secretary; Médecins Sans Frontières (MSF), Brazil (until Sept. 2013)

Sue Rice, Director, Strategic Planning, DNDi, Switzerland

Tatiana Zanotti, Secretary; Médecins Sans Frontières (MSF), Brazil (as of Oct. 2013)

• Fiscal Council

• Advisory board

Carlos Morel, Center for Technological Development in Health (CUTS/Fiocruz), Brazil (until Sept. 2013)

Sergio Alejandro Sosa-Estani, Ministry of Health, Argentina (as of Oct. 2013)

Jorge Bermudez, Oswaldo Cruz Foundation (Fiocruz), Brazil (as of Oct. 2013)
EXECUTIVE TEAM

DND Headquarters, Geneva
Bernard Pécoul, Executive Director
Graeme Bilbe, Research & Development Director
(Jean-François Alesandrini, Fundraising, Communication & Advocacy Director)
Ralf de Coulon, Finance, Human Resources & Administration Director (until Sept. 2013)
Robert Don, Discovery & Pre-clinical Director
Jean-Pierre Paccaud, Business Development Director
Thomas Saugnac, Operations Director
Nathalie Strub Wourgaft, Medical Development Director
Laurence Vielfaure, Finance & Planning Director (as of Jan. 2014)

DND Regional Offices and Affiliate
Rachel Cohen, Regional Executive Director, USA
Fumiko Hirabayashi, DND Representative, Japan
Visweswaran Navaratnam, Head of Regional Office, Malaysia
Bhawna Sharma, Director, Research and Development Operations, India
Eric Stobbaerts, Director of Regional Office, Brazil
Monique Wasunna, Director of Regional Office, Kenya

DND/Team Worldwide

• Headquarters
   Jorge Alvar; Fabiana Alves; Byron Arana; Clélia Bardonnet; Hana Bilak (until June 2013); Séverine Blesson; Raphaël Bonacchi; Pascale Boulet (until July 2013); Phouttasone Bouppha; Stéphanie Brailard; Thi Hanh Cao; Gwenaëlle Carn; Pascal Carpentier (as of Feb. 2014); Eric Chatelain; Christine Crettenand; Brigitte Crottly; Violaine Dällenbach; Sophie Delhomme; Graciela Diap; Sally Ellis (until Aug. 2013); Julia Fährmann; Anna FitzGerald; Caroline Gaere Gardaz; Emilie Gutierrez (as of Jan. 2014); Alexandra Heumber; Nina Holzhauer; Jean-Robert Ioset; Michelle Joannis; Dominique Junod-Moser; Jean-René Kiechel; Marc Lallemant; Gabrielle Landry Chappuis; Delphine Launay; Janice Lee; Sandrine Lo Iacono; Christophine Marty-Moreau; Janine Millier; Béatrice Mouton; Charles Mowbray; Nataliya Omelchuk; Claudia Pena Rossi (as of March 2014); Sophie Raffée; Sylvie Renaudin; Isabela Ribeiro; Stephen Robinson; Ivan Scandale; Rebecca Schmitt; François Simon (as of Feb. 2014); Olena Sushchenko; Antoine Tarral; Donia Tourki; Olaf Valverde; Susan Wells.

• Regional Offices

AFRICA
DRC
Chirac Bulanga; Mamie Thérèse Benyi Ndumba; Arthur Bongo Nsokuba; Augustin Kadima Ebeja; Richard Mumbi Mbumba; Baudoin Maki Di Onguku.

KENYA
John Ambasa; Simon Bolo; Nicholas Bonyo; Josephine Kesusu; Robert Kimutai; Joy Malongo; Peninah Menza; Brian Mutinda; Godfrey Nyakaya; Michael Ochieng; Seth Okeyo; Renee Olende; Raymond Omollo; Truphosa Omollo; Rhoda Owiti; Punam Amratia (as of Feb. 2014); Moses Waweru.

ASIA
INDIA
Md. Akram; Sharmila Das; Vishal Goyal; Raj Kishore Rai; Manav Kumar (as of April 2014); Pankaj Kumar; Sachin Kumar; Babita Papneja; Abhijit Sharma; Vikash Kumar Sharma; Anurag Singh; Ranvijay Singh.

JAPAN
Emi Nakamura.

MALAYSIA
Teresa Chan Wai Theng; Peng Lin Wong.

LATIN AMERICA
BRAZIL
Mariana Abdalla; Mariana Abi-Saab; Laura Acebal (as of Feb 2014); Carolina Batista (as of April 2014); Bethania Blum de Oliveira; Marina Boni (as of Jan. 2014); Erika Correia; Thalita Cardoso; Letícia Cavalcanti; Igor Moraes; Betina Moura; Joëlle Rode; Glaucia Santina; Diego Santos.

NORTH AMERICA
USA
Erin Conklin (until April 2013); Jennifer Duran; Richard Feiner; Robert Grembowitz; Jennifer Katz; Oliver Yun.
Stable increase in expenditure

DNDi expenditure totals EUR 181 million since its inception in 2003. In 2013, expenditure amounted to EUR 31 million, +4% as compared to 2012. This relative stability is mainly due to a contingency plan implemented mid-year 2013 as key funding decisions were delayed between April and August 2013. Full portfolio activity resumed in Q3 2013. The operating gain of EUR 0.231 million is partly cancelled because of exchange rate loss (EUR 0.116).

113 FTEs worldwide, the majority in Regional Offices

In 2013, DNDi recruited an additional 6 FTEs (+18 FTEs in 2012), mainly in Regional Offices (ROs): +5 FTEs in Nairobi, New Delhi, Kinshasa, New York, and Rio de Janeiro (+9%) and +1 FTE at Headquarters in Geneva (+2%). This trend towards greater growth in regions, underway since 2012, reached new levels in 2013: Regional Office staff (52%) is higher than Headquarter staff (48%), in accordance with the Business Plan 2011-2018.

STATEMENT OF ACTIVITIES 2003-2013

In '000' EUR

<table>
<thead>
<tr>
<th>Year</th>
<th>Total Income</th>
<th>Total Expenditure</th>
<th>Net Surplus for the year</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003-4</td>
<td>29,963</td>
<td>27,876</td>
<td>2,087</td>
</tr>
<tr>
<td>2005</td>
<td>31,126</td>
<td>31,011</td>
<td>115</td>
</tr>
<tr>
<td>2006</td>
<td>29,896</td>
<td>31,126</td>
<td>-227</td>
</tr>
<tr>
<td>2007</td>
<td>26,000</td>
<td>29,896</td>
<td>-3,896</td>
</tr>
<tr>
<td>2008</td>
<td>22,000</td>
<td>26,000</td>
<td>-4,000</td>
</tr>
<tr>
<td>2009</td>
<td>18,000</td>
<td>22,000</td>
<td>-4,000</td>
</tr>
<tr>
<td>2010</td>
<td>14,000</td>
<td>18,000</td>
<td>-4,000</td>
</tr>
<tr>
<td>2011</td>
<td>10,000</td>
<td>14,000</td>
<td>-4,000</td>
</tr>
<tr>
<td>2012</td>
<td>6,000</td>
<td>10,000</td>
<td>-4,000</td>
</tr>
<tr>
<td>2013</td>
<td>2,000</td>
<td>6,000</td>
<td>-4,000</td>
</tr>
</tbody>
</table>

HUMAN RESOURCES EVOLUTION 2004-2013

<table>
<thead>
<tr>
<th>Year</th>
<th>Total full-time equivalent (FTEs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>107</td>
</tr>
<tr>
<td>2005</td>
<td>113</td>
</tr>
<tr>
<td>2006</td>
<td>107</td>
</tr>
<tr>
<td>2007</td>
<td>113</td>
</tr>
<tr>
<td>2008</td>
<td>107</td>
</tr>
<tr>
<td>2009</td>
<td>113</td>
</tr>
<tr>
<td>2010</td>
<td>107</td>
</tr>
<tr>
<td>2011</td>
<td>113</td>
</tr>
<tr>
<td>2012</td>
<td>113</td>
</tr>
<tr>
<td>2013</td>
<td>113</td>
</tr>
</tbody>
</table>

Steady growth in expenditure

DNDi expenditure totals EUR 181 million since its inception in 2003. In 2013, expenditure amounted to EUR 31 million, +4% as compared to 2012. This relative stability is mainly due to a contingency plan implemented mid-year 2013 as key funding decisions were delayed between April and August 2013. Full portfolio activity resumed in Q3 2013. The operating profit of EUR 0.231 million is partly cancelled because of exchange rate loss (EUR 0.116).

SUSTAINED GROWTH IN REGIONAL OFFICES AND

In 2013, DNDi recruited an additional 6 FTEs (+18 FTEs in 2012), mainly in Regional Offices (ROs): +5 FTEs in Nairobi, New Delhi, Kinshasa, New York, and Rio de Janeiro (+9%) and +1 FTE at Headquarters in Geneva (+2%). This trend towards greater growth in regions, underway since 2012, reached new levels in 2013: Regional Office staff (52%) is higher than Headquarter staff (48%), in accordance with the Business Plan 2011-2018.
On track towards Business Plan targets
2013 SOCIAL MISSION BREAKDOWN: 86.5% OF EXPENDITURE

In 2013, DNDi’s non-social mission ratio remained stable, as the same level of management and fundraising expenditure was maintained from 2012. Other social mission ratio (including capacity strengthening and advocacy activities) increased significantly in 2013 (from 10.3% in 2012 to 11.6% in 2013) mainly due to DNDi’s 10-year anniversary activities and events in Nairobi and Paris (events and publication budgets increased by 58% in 2013 compared to 2012). In addition, the involvement of Regional Offices (ROs) in Kenya, Brazil, and North America in advocacy and communication activities increased in 2013 (+48%). Two ROs were strengthened in 2013: the India office moved to a new and bigger office and the Kenya office increased general activities (international conferences, training, travel, meetings). The increase of other social mission ratio (+1.3%) compensated the decrease of the R&D ratio (-1.3%).

Stable public-private ratio among DNDi’s partners and service providers

Comparison of the public institutional sector (research institutes, public hospitals, academic groups, universities, PDPs, and other not-for-profit organizations) and the private sector (pharmaceutical and biotechnology companies and contract research organizations (CROs)).

Partnerships in endemic regions increase to support clinical activities
MAIN R&D PARTNERS AND SERVICE PROVIDERS PER CONTINENT with financial compensation over EUR 5,000

In 2013, the number of partners and service providers with which DNDi had business relations valued at over EUR 5,000 increased by 15% (114 in 2013 as compared to 99 in 2012). The main increase is in Asia (+33%; 16 partners in 2013 compared to 12 partners in 2012), reflecting growth of the India implementation study (Bihar State support, partners for logistical support). In Africa, the increase reflects additional sites for the HAT fexinidazole study in DRC. In the Americas, the increase is due to the new clinical study for CL, and in Europe it is due to project progression such as that for filaria, paediatric HIV, and preparations for new VL combinations.

Steady growth in number of partnerships
NUMBER OF CONTRACTS SIGNED ANNUALLY*

The evolution of contracts finalized annually follows a trend similar to that of R&D Partners & Service Providers with a financial compensation of over EUR 5,000. There is a regular annual increase between 5% and 15%, with 5% in 2013.

* Except confidentiality agreements